Richmond Pharmacology is excited to confirm our attendance at BioJapan 2025, Asia’s leading biotechnology partnering event, taking place in Yokohama from 8–10 October.

Representing Richmond at BioJapan 2025:

  • Dr Jörg Täubel, Chief Executive Officer
  • Stephen Wilkinson, Business Development Manager
  • Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
  • Minoru Takada, Japanese Business Development Executive

We look forward to connecting with global partners, sharing insights, and exploring opportunities in:

  • Early-phase trials for biologics and advanced therapies
  • UK–Japan collaboration in gene editing and RNA medicines
  • Regulatory strategy across Asia and Europe
  • Bridging studies and multi-regional trial design
  • Patient-centric and adaptive trial models

If you’re attending BioJapan 2025 and are looking to collaborate in translational research or clinical development, get in touch to arrange a meeting: info@richmondpharmacology.com

Learn more: BioJapan/ 再生医療JAPAN/ healthTECH JAPAN

Latest news

Participant-Centred Recruitment and Retention: Driving Faster Answers in Clinical Trials.

December 18, 2025
Richmond Pharmacology is proud to announce the publication of an editorial by Elizabeth Romano, Director of Communications and Participant Engagement, in the Winter 2025 issue of the Journal for Clinical Studies.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event